What is NATIONAL HEALTHCRE PPTY's earnings per share (EPS)?

NATIONAL HEALTHCRE PPTY (HLTC) reported diluted earnings per share of -$2.51 for fiscal year 2025. This represents a 65.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

NATIONAL HEALTHCRE PPTY (HLTC) Financials

HLTC

Trailing 12 months to June 30, 2026

Revenue $344.3M -1.2% YoY

Net Income -$45.0M +43.8% YoY

EPS (Diluted) -$1.88 +43.2% YoY

Operating Cash Flow $50.7M +149.8% YoY

Market Cap $337.0M as of Oct 9, 2026

Price / Sales 1.0x on $344.3M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 0.3x on $1.1B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HLTC SEC filings page.

NATIONAL HEALTHCRE PPTY (HLTC) reported $344.3M in revenue over the twelve months to Jun 30, 2026, down 1.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HLTC FY2025 2026-10-03

The business returned to positive operating income in 2025, but financing costs and weak cash conversion still kept reported earnings negative.

Operating income turned positive at $3.3M while revenue fell from FY2024's level, so the prior operating loss was driven more by below-gross-profit charges than by the modest top-line change. Gross margin narrowed from 37.4% to 36.1%, making the recovery look like a change in other operating charges rather than a margin-led expansion.

Cash conversion swung from -$79.8M to $7.0M across the latest two years, but FY2025 EBITDA was $81.6M; the wide gap indicates that operating performance is still not converting cleanly into cash. The continuing net loss of $57.7M alongside interest expense of $61.3M shows financing costs remain large enough to absorb the operating recovery.

Total assets fell from $1.95B to $1.71B across the latest two years, indicating a smaller balance-sheet footprint rather than expansion. Yet debt-to-equity held near 1.8x as equity also contracted, so the shrinkage did not materially improve the capital structure's leverage.

Financial Health Signals

Financial health score not available

NATIONAL HEALTHCRE PPTY does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

4/7

NATIONAL HEALTHCRE PPTY passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Mixed

N/A

NATIONAL HEALTHCRE PPTY reported a net loss of $57.7M while generating $7.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk

0.05x

NATIONAL HEALTHCRE PPTY earns $0.05 in operating income for every $1 of interest expense ($3.3M vs $61.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$87.5M

YoY+2.6%

QoQ+1.4%

5Y CAGR+1.5%

10Y CAGR+1.4%

NATIONAL HEALTHCRE PPTY generated $87.5M in revenue in Q2 2026. This represents an increase of 2.6% from the same quarter a year earlier. Against the prior quarter it is up 1.4%.

EBITDA

$22.9M

YoY+75.8%

QoQ-17.8%

5Y CAGR+5.7%

NATIONAL HEALTHCRE PPTY's EBITDA was $22.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 75.8% from the same quarter a year earlier. Against the prior quarter it is down 17.8%.

Net Income

-$5.4M

YoY+74.1%

QoQ-25.8%

NATIONAL HEALTHCRE PPTY reported -$5.4M in net income in Q2 2026. This represents an increase of 74.1% from the same quarter a year earlier. Against the prior quarter it is down 25.8%.

EPS (Diluted)

-$0.13

NATIONAL HEALTHCRE PPTY earned -$0.13 per diluted share (EPS) in Q2 2026.

Cash & Balance Sheet

Cash & Debt

$245.7M

YoY+421.4%

QoQ+365.3%

5Y CAGR+39.4%

10Y CAGR+19.7%

NATIONAL HEALTHCRE PPTY held $245.7M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

Diluted avg 62M

NATIONAL HEALTHCRE PPTY had a weighted average of 62M diluted shares in Q2 2026; the shares outstanding count is not reported for that period.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

38.2%

YoY+1.7pp

QoQ-0.5pp

5Y change+1.7pp

NATIONAL HEALTHCRE PPTY's gross margin was 38.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 1.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.5 percentage points.

Operating Margin

5.8%

YoY+12.3pp

QoQ-5.9pp

5Y change+8.4pp

NATIONAL HEALTHCRE PPTY's operating margin was 5.8% in Q2 2026, reflecting core business profitability. This is up 12.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.9 percentage points.

Net Margin

-6.2%

YoY+18.3pp

QoQ-1.2pp

5Y change+11.2pp

10Y change-2.2pp

NATIONAL HEALTHCRE PPTY's net profit margin was -6.2% in Q2 2026, showing the share of revenue converted to profit. This is up 18.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.2 percentage points.

Return on Equity

-0.5%

YoY+2.7pp

QoQ+0.2pp

5Y change+0.9pp

10Y change-0.3pp

NATIONAL HEALTHCRE PPTY's ROE was -0.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 2.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.2 percentage points.

Capital Allocation

None of these metrics is reported for Q2 2026.

HLTC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HLTC quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Revenue	$344.3M	$342.3M-3.3%	$353.8M+2.3%	$345.9M+3.0%	$335.8M+2.0%	$329.4M-13.7%	$381.6M+1.8%	$374.9M+3.5%	$362.4M+16.5%	$311.2M+2.8%	$302.6M+22.3%	$247.5M+323.5%	$58.4M+3116.2%	$1.8M
Gross Profit	$130.4M	$123.4M-6.8%	$132.3M+3.3%	$128.1M+4.7%	$122.4M-0.9%	$123.5M-10.5%	$138.1M-1.9%	$140.7M-0.5%	$141.4M+13.2%	$124.9M-4.3%	$130.5M+7.0%	$121.9M+284.3%	$31.7M+1771.5%	$1.7M
SG&A Expenses	$26.3M	$24.2M+7.8%	$22.4M+18.6%	$18.9M+9.5%	$17.3M+2.7%	$16.8M-22.0%	$21.6M+5.1%	$20.5M+18.8%	$17.3M+10.2%	$15.7M+29.5%	$12.1M+24.4%	$9.7M+174.9%	$3.5M+3304.8%	$104K
Operating Income	$11.0M	$3.3M+102.7%	-$123.5M-2507.5%	-$4.7M+85.0%	-$31.5M+15.7%	-$37.4M-88.4%	-$19.9M+37.5%	-$31.8M-900.9%	-$3.2M+74.0%	-$12.2M-269.4%	-$3.3M+90.7%	-$35.6M-3.7%	-$34.3M-15794.0%	-$216K
EBITDA	N/A	$81.6M+306.6%	-$39.5M-150.5%	$78.1M+54.7%	$50.5M+18.9%	$42.5M-30.5%	$61.2M+24.2%	$49.2M-38.5%	$80.0M+22.3%	$65.4M-31.5%	$95.6M+12.0%	$85.3M+1667.7%	-$5.4M-732.1%	$861K
Interest Expense	$58.3M	$61.3M-11.8%	$69.4M+5.1%	$66.1M+27.7%	$51.7M+8.0%	$47.9M-7.0%	$51.5M-8.1%	$56.1M+13.3%	$49.5M+63.5%	$30.3M+52.2%	$19.9M+92.0%	$10.4M+191.0%	$3.6M	$0
Income Tax	$291K	$161K-38.5%	$262K-13.5%	$303K+50.7%	$201K-1.0%	$203K-95.0%	$4.1M+917.8%	$399K+102.5%	$197K-69.6%	$647K+131.0%	-$2.1M+30.0%	-$3.0M-627.1%	$565K+11200.0%	$5K
Net Income	-$45.0M	-$57.7M+69.7%	-$190.3M-162.9%	-$72.4M+9.1%	-$79.6M+6.8%	-$85.4M-13.2%	-$75.5M+14.3%	-$88.1M-67.0%	-$52.8M-24.0%	-$42.5M-103.8%	-$20.9M+50.0%	-$41.7M-10.8%	-$37.7M-16948.9%	-$221K
EPS (Basic)	N/A	-$2.51+65.1%	-$7.19-136.5%	-$3.04+7.9%	-$3.30-302.4%	-$0.82-10.8%	-$0.74+15.9%	-$0.88	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$1.88	-$2.51+65.1%	-$7.19	-$3.04+7.9%	-$3.30	-$0.82-10.8%	-$0.74+15.9%	-$0.88	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	28M+0.1%	28M	28M+0.1%	28M	113M+6.5%	106M+6.0%	100M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$87.5M+2.6%	$86.3M-0.2%	$84.5M-3.7%	$86.0M-3.3%	$85.3M-3.9%	$86.4M-2.1%	$87.7M+1.1%	$88.9M+3.8%
Gross Profit	$33.4M+7.2%	$33.4M+16.7%	$31.5M-4.2%	$32.2M-1.1%	$31.2M-7.9%	$28.6M-13.8%	$32.8M+6.8%	$32.5M+3.7%
SG&A Expenses	$6.6M+30.1%	$5.5M+11.7%	$8.5M+55.4%	$5.7M+3.1%	$5.1M+8.7%	$4.9M-27.7%	$5.5M+14.1%	$5.5M+15.8%
Operating Income	$5.1M+192.2%	$10.1M-22.4%	-$6.6M-523.8%	$2.4M+111.3%	-$5.5M+94.5%	$13.0M+1262.9%	-$1.1M+84.0%	-$20.9M-2194.5%
EBITDA	$22.9M+75.8%	$27.8M-24.2%	$11.4M-41.9%	$20.4M+10004.9%	$13.0M+116.6%	$36.7M+87.2%	$19.6M+32.8%	-$206K-101.0%
Interest Expense	$12.7M-19.7%	$14.7M+1.0%	$15.9M-8.4%	$15.1M-16.4%	$15.8M-10.8%	$14.5M-11.3%	$17.3M+9.0%	$18.0M+14.5%
Income Tax	$47K	$77K+1383.3%	$101K-20.5%	$66K	$0-100.0%	-$6K-108.6%	$127K+115.3%	$0-100.0%
Net Income	-$5.4M+74.1%	-$4.3M-182.6%	-$22.8M-33.9%	-$12.5M+69.3%	-$20.8M+82.2%	-$1.5M+90.3%	-$17.0M+31.5%	-$40.8M-152.8%
EPS (Basic)	-$0.13+84.7%	-$0.27-50.0%	-$0.92-27.8%	-$0.56+64.1%	-$0.85+80.0%	-$0.18+73.1%	-$0.72+27.3%	-$1.56-126.1%
EPS (Diluted)	-$0.13	-$0.27	-$0.92-27.8%	-$0.56+64.1%	-$0.85	-$0.18	-$0.72	-$1.56
Diluted Shares (Avg)	62M	28M	N/A	28M0.0%	28M	28M	N/A	28M

Not reported in any period shown, so not listed: Cost of Revenue, R&D Expenses.

HLTC Balance Sheet

HLTC quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$1.7B-12.0%	$1.9B-9.3%	$2.1B-1.6%	$2.2B-1.5%	$2.2B-3.2%	$2.3B-1.7%	$2.3B-2.2%	$2.4B+0.2%	$2.4B+8.1%	$2.2B-3.4%	$2.3B+22.2%	$1.9B+1059.6%	$160.2M
Cash & Equivalents	$57.6M+166.1%	$21.7M-53.3%	$46.4M-13.5%	$53.7M-10.2%	$59.7M-17.4%	$72.4M-24.4%	$95.7M+23.8%	$77.3M-18.0%	$94.2M+222.2%	$29.2M+19.4%	$24.5M-86.6%	$182.6M+63.3%	$111.8M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$9.3M+58.2%	$5.8M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.1B-11.8%	$1.3B+0.9%	$1.2B+5.4%	$1.2B+0.6%	$1.2B-11.4%	$1.3B+8.8%	$1.2B+7.2%	$1.1B+11.9%	$1.0B+47.4%	$689.4M+3.2%	$668.0M+432.2%	$125.5M+6002.7%	$2.1M
Total Equity	$600.1M-12.3%	$684.6M-23.4%	$894.2M-9.9%	$992.6M-4.0%	$1.0B+8.0%	$957.0M-13.1%	$1.1B-10.7%	$1.2B-8.5%	$1.3B-9.9%	$1.5B-6.1%	$1.6B-7.5%	$1.7B+988.9%	$158.1M
Retained Earnings	N/A	N/A	N/A	-$1.5B-14.0%	-$1.3B-15.7%	-$1.1B-14.1%	-$971.2M-20.7%	-$804.3M-20.9%	-$665.0M-36.7%	-$486.6M-53.8%	-$316.3M-144.4%	-$129.4M-3236.9%	-$3.9M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$2.0B+12.4%	$1.7B-7.3%	$1.7B-12.0%	$1.7B-12.9%	$1.8B-16.8%	$1.8B-14.1%	$1.9B-9.3%	$2.0B-8.0%
Cash & Equivalents	$245.7M+421.4%	$52.8M-26.0%	$57.6M+166.1%	$47.1M+43.2%	$47.1M+60.0%	$71.4M+149.0%	$21.7M-53.3%	$32.9M-35.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$7.2M-23.1%	$9.2M+13.5%	$9.3M+58.2%	$10.2M	$9.3M	$8.1M	$5.8M	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$919.0M-16.9%	$1.1B-4.4%	$1.1B-11.8%	$1.1B-14.2%	$1.1B-18.1%	$1.2B-7.8%	$1.3B+0.9%	$1.3B+4.7%
Total Equity	$1.1B+62.9%	$592.2M-12.2%	$600.1M-12.3%	$627.2M-10.7%	$647.0M-14.5%	$674.6M-23.1%	$684.6M-23.4%	$702.6M-24.8%

Not reported in any period shown, so not listed: Current Assets, Inventory, Goodwill, Current Liabilities, Non-Current Liabilities, Long-Term Debt, Retained Earnings.

HLTC Cash Flow Statement

HLTC quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	$50.7M	$7.0M+108.7%	-$79.8M-469.2%	$21.6M-23.6%	$28.3M-27.2%	$38.9M-7.0%	$41.8M-11.8%	$47.4M-12.5%	$54.2M-15.3%	$64.0M-18.7%	$78.7M+14.6%	$68.7M+1162.3%	-$6.5M-746.2%	-$764K
Depreciation & Amortization	N/A	$78.3M-6.9%	$84.1M+1.4%	$82.9M+1.0%	$82.1M+2.7%	$79.9M-1.4%	$81.1M0.0%	$81.0M-2.6%	$83.2M+7.2%	$77.6M-21.5%	$98.9M-18.2%	$120.9M+318.6%	$28.9M+2582.4%	$1.1M
Stock-Based Compensation	N/A	$3.8M+514.4%	$613K-33.3%	$919K-22.4%	$1.2M-10.8%	$1.3M-1.2%	$1.3M+2.0%	$1.3M+6.0%	$1.2M+164.7%	$470K+193.8%	$160K+166.7%	$60K-17.8%	$73K+356.3%	$16K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$16.7M+29.5%	$12.9M+56.0%	$8.3M+10.7%	$7.5M+8.6%	$6.9M+753.2%	$807K	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$30.7M-25.6%	$41.2M-25.9%	$55.7M-21.8%	$71.2M+15.3%	$61.8M+949.8%	-$7.3M-851.8%	-$764K
Investing Cash Flow	-$115.1M	$69.8M+9.1%	$64.0M+201.8%	-$62.8M-50.3%	-$41.8M+12.8%	-$47.9M+41.9%	-$82.5M-78.4%	-$46.2M+59.8%	-$115.1M+40.8%	-$194.4M-918.3%	-$19.1M+96.6%	-$556.8M+63.6%	-$1.5B-3193.9%	-$46.5M
Financing Cash Flow	$263.6M	-$42.4M-3047.7%	-$1.3M-102.4%	$56.0M+1105.5%	$4.6M+13.8%	$4.1M-79.0%	$19.4M+1.8%	$19.1M-61.6%	$49.7M-75.1%	$199.8M+459.6%	-$55.6M-116.7%	$332.9M-79.3%	$1.6B+911.1%	$159.1M
Dividends Paid	N/A	N/A	N/A	N/A	$0	$0-100.0%	$31.4M-39.0%	$51.4M-7.1%	$55.3M-27.9%	$76.7M+1.7%	$75.4M+13.9%	$66.2M+88.3%	$35.2M+2594.6%	$1.3M
Share Buybacks	N/A	N/A	N/A	N/A	$0	$0-100.0%	$10.5M-50.1%	$21.1M+48.7%	$14.2M-57.7%	$33.6M+175.8%	$12.2M+17.0%	$10.4M+1824.8%	$541K	$0

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$21.6M+168.3%	$9.0M+142.5%	$10.0M+54.3%	$10.2M+110.7%	$8.1M+26.0%	-$21.2M-934.8%	$6.5M+22.6%	-$95.2M-1776.4%
Depreciation & Amortization	$17.8M-3.9%	$17.7M-25.2%	$18.0M-13.0%	$18.0M-13.0%	$18.5M-15.5%	$23.7M+14.3%	$20.7M-3.1%	$20.7M-0.3%
Stock-Based Compensation	$1.6M+166.7%	$612K	N/A	N/A	$600K	$0-100.0%	N/A	N/A
Investing Cash Flow	-$103.4M-5343.7%	-$5.4M-106.9%	-$3.3M-161.6%	-$3.0M-104.1%	-$1.9M+43.5%	$78.0M+738.9%	$5.4M+139.2%	$74.1M+605.2%
Financing Cash Flow	$277.5M+1044.3%	-$5.4M-21.0%	-$712K+96.9%	-$7.8M-131.1%	-$29.4M-2022.2%	-$4.5M+13.9%	-$22.7M-365.4%	$25.0M+579.2%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

HLTC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HLTC quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Gross Margin	36.0%-1.4pp	37.4%+0.4pp	37.0%+0.6pp	36.4%-1.1pp	37.5%+1.3pp	36.2%-1.4pp	37.5%-1.5pp	39.0%-1.1pp	40.1%-3.0pp	43.1%-6.1pp	49.3%-5.0pp	54.3%-39.0pp	93.3%
Operating Margin	1.0%+35.9pp	-34.9%-33.6pp	-1.4%+8.0pp	-9.4%+2.0pp	-11.4%-6.2pp	-5.2%+3.3pp	-8.5%-7.6pp	-0.9%+3.0pp	-3.9%-2.8pp	-1.1%+13.3pp	-14.4%+44.4pp	-58.8%-46.9pp	-11.9%
Net Margin	-16.9%+36.9pp	-53.8%-32.9pp	-20.9%+2.8pp	-23.7%+2.2pp	-25.9%-6.2pp	-19.8%+3.7pp	-23.5%-8.9pp	-14.6%-0.9pp	-13.7%-6.8pp	-6.9%+10.0pp	-16.9%+47.6pp	-64.5%-52.3pp	-12.2%
Return on Equity	-9.6%+18.2pp	-27.8%-19.7pp	-8.1%-0.1pp	-8.0%+0.3pp	-8.3%-0.4pp	-7.9%+0.1pp	-8.0%-3.7pp	-4.3%-1.1pp	-3.2%-1.8pp	-1.4%+1.2pp	-2.6%-0.4pp	-2.2%-2.1pp	-0.1%
Return on Assets	-3.4%+6.4pp	-9.8%-6.4pp	-3.4%+0.3pp	-3.6%+0.2pp	-3.9%-0.6pp	-3.3%+0.5pp	-3.8%-1.6pp	-2.2%-0.4pp	-1.8%-0.8pp	-0.9%+0.9pp	-1.8%+0.2pp	-2.0%-1.9pp	-0.1%
Debt-to-Equity	1.850.0x	1.83+0.4x	1.39+0.2x	1.19+0.1x	1.14-0.2x	1.39+0.3x	1.11+0.2x	0.92+0.2x	0.75+0.3x	0.460.0x	0.42+0.3x	0.07+0.1x	0.01
Asset Turnover	0.200.0x	0.180.0x	0.160.0x	0.150.0x	0.150.0x	0.170.0x	0.160.0x	0.150.0x	0.130.0x	0.140.0x	0.11+0.1x	0.030.0x	0.01
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	8.2%-3.2pp	11.4%-6.5pp	17.9%-5.6pp	23.5%-1.4pp	25.0%+37.4pp	-12.4%+29.6pp	-42.0%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	38.2%+1.7pp	38.7%+5.6pp	37.2%-0.2pp	37.4%+0.8pp	36.5%-1.6pp	33.1%-4.5pp	37.4%+2.0pp	36.6%0.0pp
Operating Margin	5.8%+12.3pp	11.7%-3.4pp	-7.8%-6.6pp	2.8%+26.3pp	-6.5%	15.1%+16.3pp	-1.2%+6.4pp	-23.5%-22.5pp
Net Margin	-6.2%+18.3pp	-5.0%-3.2pp	-27.0%-7.6pp	-14.6%+31.3pp	-24.4%	-1.8%+15.9pp	-19.4%+9.2pp	-45.8%-27.0pp
Return on Equity	-0.5%+2.7pp	-0.7%-0.5pp	-3.8%-1.3pp	-2.0%+3.8pp	-3.2%+12.2pp	-0.2%+1.6pp	-2.5%+0.3pp	-5.8%-4.1pp
Return on Assets	-0.3%+0.9pp	-0.3%-0.2pp	-1.3%-0.5pp	-0.7%+1.3pp	-1.2%+4.4pp	-0.1%+0.7pp	-0.9%+0.3pp	-2.0%-1.3pp
Debt-to-Equity	0.87-0.8x	1.86+0.2x	1.850.0x	1.76-0.1x	1.71-0.1x	1.71+0.3x	1.83+0.4x	1.83+0.5x
Asset Turnover	0.040.0x	0.050.0x	0.050.0x	0.050.0x	0.050.0x	0.050.0x	0.050.0x	0.040.0x

Not reported in any period shown, so not listed: Current Ratio, FCF Margin.

Where NATIONAL HEALTHCRE PPTY Ranks

Frequently Asked Questions

What is NATIONAL HEALTHCRE PPTY's annual revenue?

NATIONAL HEALTHCRE PPTY (HLTC) reported $342.3M in total revenue for fiscal year 2025. This represents a -3.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is NATIONAL HEALTHCRE PPTY's revenue growing?

NATIONAL HEALTHCRE PPTY (HLTC) revenue declined by 3.3% year-over-year, from $353.8M to $342.3M in fiscal year 2025.

Is NATIONAL HEALTHCRE PPTY profitable?

No, NATIONAL HEALTHCRE PPTY (HLTC) reported a net income of -$57.7M in fiscal year 2025, with a net profit margin of -16.9%.

What is NATIONAL HEALTHCRE PPTY's EBITDA?

NATIONAL HEALTHCRE PPTY (HLTC) had EBITDA of $81.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is NATIONAL HEALTHCRE PPTY's gross margin?

NATIONAL HEALTHCRE PPTY (HLTC) had a gross margin of 36.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is NATIONAL HEALTHCRE PPTY's operating margin?

NATIONAL HEALTHCRE PPTY (HLTC) had an operating margin of 1.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is NATIONAL HEALTHCRE PPTY's net profit margin?

NATIONAL HEALTHCRE PPTY (HLTC) had a net profit margin of -16.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is NATIONAL HEALTHCRE PPTY's return on equity (ROE)?

NATIONAL HEALTHCRE PPTY (HLTC) has a return on equity of -9.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is NATIONAL HEALTHCRE PPTY's operating cash flow?

NATIONAL HEALTHCRE PPTY (HLTC) generated $7.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are NATIONAL HEALTHCRE PPTY's total assets?

NATIONAL HEALTHCRE PPTY (HLTC) had $1.7B in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does NATIONAL HEALTHCRE PPTY have outstanding?

NATIONAL HEALTHCRE PPTY (HLTC) had 28M shares outstanding as of fiscal year 2025.

What is NATIONAL HEALTHCRE PPTY's debt-to-equity ratio?

NATIONAL HEALTHCRE PPTY (HLTC) had a debt-to-equity ratio of 1.85 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is NATIONAL HEALTHCRE PPTY's return on assets (ROA)?

NATIONAL HEALTHCRE PPTY (HLTC) had a return on assets of -3.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is NATIONAL HEALTHCRE PPTY's P/E ratio?

NATIONAL HEALTHCRE PPTY (HLTC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $337.0M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is NATIONAL HEALTHCRE PPTY's price-to-sales ratio?

NATIONAL HEALTHCRE PPTY (HLTC) trades at 1.0x sales, its market capitalization divided by revenue of $344.3M revenue, trailing 12 months to June 30, 2026. The market capitalization is $337.0M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is NATIONAL HEALTHCRE PPTY's Piotroski F-Score?

NATIONAL HEALTHCRE PPTY (HLTC) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are NATIONAL HEALTHCRE PPTY's earnings high quality?

NATIONAL HEALTHCRE PPTY (HLTC) reported a net loss of $57.7M while generating $7.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can NATIONAL HEALTHCRE PPTY cover its interest payments?

NATIONAL HEALTHCRE PPTY (HLTC) has an interest coverage ratio of 0.05x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.